Citations 2
Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
Yin, J., Lazaryan, Aleksandr , Geethakumari, Praveen Ramakrishnan , Hernandez‐Ilizaliturri, Francisco J. , Shune, Leyla , Reeder, Craig B. , Mikula, E., Strand, Carina, Zornikova, Ksenia V. , Bagaev, A., Fowler, Nathan , Whitaker, Katherine R. , Ferre, Rob, Costello, Brian A. , Yang, Zhizhang, Tang, Xinyi , Ansell, Stephen M. , Soekojo, Cinnie Yentia , Kline, Justin Paul , Bartlett, Nancy L. , Awan, Farrukh T. , Karmali, Reem , Lansigan, Frederick , Diefenbach, Catherine , Sharon, Elad , Strand, C., Postovalova, Ekaterina , Kotlov, Nikita , Whitaker, K. R., Ferre, R. Leon, Villasboas, José C.
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 592-594
Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometry
Niu, Airu, Whitaker, Kristen , Yang, Zhizhang, Kim, Hyo Jin , Novak, Anne J. , Ansell, Stephen M. , Niu, A., Whitaker, K., Soekojo, Cinnie Yentia , Villasboas, José C.
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 266-267